SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
4.170
+0.190 (4.77%)
At close: Feb 6, 2026, 4:00 PM EST
4.150
-0.020 (-0.48%)
After-hours: Feb 6, 2026, 7:13 PM EST

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
199356330340-
Market Cap Growth
486.10%-44.79%113.36%-91.25%--
Enterprise Value
9496627336-
Last Close Price
4.173.796.885.9078.10-
PS Ratio
1730.8126.4828.331.245.58-
PB Ratio
1.201.351.110.968.81-
P/TBV Ratio
1.201.351.110.968.81-
P/OCF Ratio
----170.89-
EV/Sales Ratio
818.046.9129.321.145.51-
Debt / Equity Ratio
0.040.180.100.190.220.21
Debt / EBITDA Ratio
-----0.38
Asset Turnover
0.000.020.030.360.881.48
Quick Ratio
10.332.615.231.371.563.00
Current Ratio
10.502.985.451.471.903.12
Return on Equity (ROE)
18.56%-81.92%-95.51%-53.85%-44.21%86.15%
Return on Assets (ROA)
-22.76%-41.86%-35.30%-27.37%-12.16%34.47%
Return on Capital Employed (ROCE)
-25.00%-118.50%-52.10%-80.50%-24.50%45.20%
Earnings Yield
-2.16%-97.39%-66.52%-63.04%-5.05%-
FCF Yield
-18.93%-98.89%-39.91%-86.20%-2.64%-
Buyback Yield / Dilution
-11.66%-67.74%-26.86%-59.20%-1.21%23.30%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q